POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal…

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Readers on

mendeley: 19 Mendeley

Summary News X

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 26,696 followers.

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma https://t.co/dO30725X1V https://t.co/esyoEzvYhv

10 Nov 2022

Reply Repost Favourite

10 Nov 2022

Reply Repost Favourite

POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma https://t.co/kLfCGVMwOY

12 Sep 2022

Reply Repost Favourite

New research: POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma: Background Squamous… https://t.c

24 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.